The BIRC2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the HeLa cervical adenocarcinoma line, engineered for targeted disruption of the BIRC2 gene. This heterogeneous knockout pool provides a loss-of-function model without single-cell cloning, preserving genetic diversity while eliminating functional BIRC2. The polyclonal format facilitates robust phenotypic and mechanistic studies across a broad cellular background. As a ready-to-use tool, these cells enable direct interrogation of BIRC2-dependent pathways in a widely used cancer research model.
HeLa is an immortalized cervical epithelial cell line containing integrated HPV18 sequences, characterized by aneuploidy and high proliferation. It is a standard model in cancer biology, signal transduction, and drug response studies. The knockout derivative maintains these features while specifically eliminating BIRC2 function, allowing direct comparison to parental cells. This genetic background is ideal for studying apoptosis and NF-??B signaling in a clinically relevant tumor context.
BIRC2 is an E3 ubiquitin ligase that inhibits apoptosis and promotes NF-??B signaling. It ubiquitinates RIPK1, facilitating prosurvival complex formation, and targets caspases for degradation. BIRC2 is induced by TNF-??, IL-1??, TLR ligands, and CD40L, and it interacts with TRAF1, TRAF2, XIAP, and BIRC3. Its antiapoptotic function is antagonized by SMAC/DIABLO, which displaces it from caspases. BIRC2 also regulates NIK stability, connecting canonical and noncanonical NF-??B pathways. Gene disruption impairs these ubiquitination events, sensitizing cells to apoptotic stimuli.
In HeLa cells, BIRC2 knockout removes a critical survival factor, impairing NF-??B-dependent gene expression and enhancing sensitivity to TNF-??- and chemotherapy-induced apoptosis. This model is valuable for studying chemoresistance and the interplay between IAP family members, such as XIAP and BIRC3. Loss of BIRC2 permits direct examination of caspase-3, -7, and -9 activation, providing insights into apoptotic execution. The polyclonal population supports robust biochemical and cell-based analyses without clonal bias, enabling reliable pathway dissection.
Common applications include apoptosis assays (Annexin V/PI staining), NF-??B luciferase reporter assays, and co-immunoprecipitation to probe disrupted RIPK1 or TRAF2 interactions. Western blotting can assess caspase cleavage and I??B?? degradation, while flow cytometry facilitates multiparametric viability studies. These knockout cells are well-suited for drug resistance screens, proapoptotic compound testing, and inflammatory disease modeling. Comparative experiments with parental HeLa controls precisely attribute phenotypic changes to BIRC2 deficiency. For further information or to request a quotation, please contact Ascent Research.
